Repare Therapeutics Inc. reported positive initial data from the ongoing Phase 1 MINOTAUR clinical trial evaluating lunresertib (RP-6306) in combination with FOLFIRI in patients with advanced solid tumors. The data are being presented in a mini oral presentation by Elisa Fontana, M.D., Ph.D., Medical Director, Sarah Cannon Research Institute UK at the European Society of Medical Oncology (ESMO) gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich, Germany.unresertib is a first-in-class precision oncology small molecule PKMYT1 inhibitor that targets CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors.unresertib is being evaluated in combination with other therapies across several Phase 1 and Phase 2 clinical trials, as well as in multiple investigator-sponsored trials. Key Initial Findings from the Phase 1 MINOTAUR Clinical Trial: MINOTAUR (NCT05147350) is a Phase 1, multi-center, open-label, dose-scalation study to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of lunresertib in combination with FOLFIR I in advanced solid tumors.

Primary objectives of the study were safety and tolerability, and determination of the recommended Phase 2 dose (RP2D) and schedule. As of May 2, 2024, the cutoff date for the data presented at the ESMO GI Congress, 38 patients were enrolled in the clinical trial. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®?

platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known asRP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor.